Indian Panel Flaws Biosimilar Humira Package Insert
This article was originally published in Scrip
Executive Summary
An Indian expert panel has flagged a clutch of deficiencies in the package insert of Reliance Life Sciences' biosimilar version of AbbVie's blockbuster biologic, Humira (adalimumab), including some inconsistencies around data and dosing.